186 related articles for article (PubMed ID: 37232797)
1. Impact of Fixed-Duration Oral Targeted Therapies on the Economic Burden of Chronic Lymphocytic Leukemia in Canada.
Lachaine J; Guinan K; Aw A; Banerji V; Fleury I; Owen C
Curr Oncol; 2023 Apr; 30(5):4483-4498. PubMed ID: 37232797
[TBL] [Abstract][Full Text] [Related]
2. Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada.
Lachaine J; Beauchemin C; Guinan K; Thebault P; Aw A; Banerji V; Fleury I; Owen C
Curr Oncol; 2021 Jan; 28(1):332-345. PubMed ID: 33435341
[No Abstract] [Full Text] [Related]
3. Cost-minimisation analysis of chronic lymphocytic leukemia in Spain in the era of oral targeted therapies.
Montañés B; Casado G; Medina Á; Nieto P; Ramírez-Payer Á
Farm Hosp; 2022 Jan; 46(2):72-79. PubMed ID: 35379098
[TBL] [Abstract][Full Text] [Related]
4. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States.
Chen Q; Jain N; Ayer T; Wierda WG; Flowers CR; O'Brien SM; Keating MJ; Kantarjian HM; Chhatwal J
J Clin Oncol; 2017 Jan; 35(2):166-174. PubMed ID: 27870563
[TBL] [Abstract][Full Text] [Related]
5. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
Rogers KA; Lu X; Emond B; Côté-Sergent A; Kinkead F; Lafeuille MH; Lefebvre P; Huang Q
J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
[No Abstract] [Full Text] [Related]
7. Health-related quality of life and economic burden of chronic lymphocytic leukemia in the era of novel targeted agents.
Waweru C; Kaur S; Sharma S; Mishra N
Curr Med Res Opin; 2020 Sep; 36(9):1481-1495. PubMed ID: 32634056
[TBL] [Abstract][Full Text] [Related]
8. Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia-the Burden of Novelty.
Hilal T; Betcher JA; Leis JF
Curr Hematol Malig Rep; 2018 Aug; 13(4):237-243. PubMed ID: 29982866
[TBL] [Abstract][Full Text] [Related]
9. Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States.
Cho SK; Manzoor BS; Sail KR; Parisé H; Ravelo A; Shapouri S; Kapustyan T; Sharmokh S; Virabhak S; Davids MS; Johnson S
Pharmacoeconomics; 2020 Sep; 38(9):941-951. PubMed ID: 32383129
[TBL] [Abstract][Full Text] [Related]
10. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
11. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
Kabadi SM; Near A; Wada K; Burudpakdee C
Adv Ther; 2020 Jul; 37(7):3129-3148. PubMed ID: 32399812
[TBL] [Abstract][Full Text] [Related]
12. How I manage CLL with venetoclax-based treatments.
Wierda WG; Tambaro FP
Blood; 2020 Apr; 135(17):1421-1427. PubMed ID: 32076705
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia.
Alrawashdh N; McBride A; Erstad B; Sweasy J; Persky DO; Abraham I
Value Health; 2022 Oct; 25(10):1685-1695. PubMed ID: 35537984
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland.
Barbier M; Durno N; Bennison C; Örtli M; Knapp C; Schwenkglenks M
Eur J Health Econ; 2022 Jul; 23(5):837-846. PubMed ID: 34757508
[TBL] [Abstract][Full Text] [Related]
16. A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada.
Chatterjee A; van de Wetering G; Goeree R; Owen C; Desbois AM; Barakat S; Manzoor BS; Sail K
Pharmacoecon Open; 2023 Mar; 7(2):199-216. PubMed ID: 36334238
[TBL] [Abstract][Full Text] [Related]
17. Current and emerging investigational venetoclax-based therapies in chronic lymphocytic leukemia.
Molica S; Allsup D; Gianfelici V; Levato L; Aiello V; Bailey J; Polliack A
Expert Opin Investig Drugs; 2021 Jun; 30(6):621-633. PubMed ID: 33929928
[No Abstract] [Full Text] [Related]
18. Treatment patterns, adverse events, and economic burden in a privately insured population of patients with chronic lymphocytic leukemia in the United States.
Kabadi SM; Goyal RK; Nagar SP; Kaye JA; Davis KL
Cancer Med; 2019 Jul; 8(8):3803-3810. PubMed ID: 31144473
[TBL] [Abstract][Full Text] [Related]
19. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
Small S; Ma S
Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
[TBL] [Abstract][Full Text] [Related]
20. Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management.
Eyre TA; Hori S; Munir T
Hematol Oncol; 2022 Apr; 40(2):129-159. PubMed ID: 34713475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
